
Full profile: /officials/K000389
Source: Congress.gov · FEC
Members who have signed on to support this bill since introduction. Source: Congress.gov.
The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2025-05-19
Source: Congress.gov
This bill would allow the federal government to negotiate drug prices more aggressively and potentially tie what Americans pay for medications to prices charged in other developed countries, aiming to reduce prescription drug costs for patients and the government. The legislation would affect pharmaceutical companies, Medicare and Medicaid programs, and anyone who takes prescription drugs. It has been referred to multiple House committees for review but has not yet been voted on.
AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.
Industries and interest groups with a stake in how this bill is resolved. Compare with each member's outside-money backers on their finance page.
Why this matters: Look up any member who voted on this bill and check their finance page — do the industries listed above match the groups funding their campaigns? That's the kind of connection this tool is built to help you find.
Bills by the same sponsor or covering overlapping subjects.